Overview
Livagen is a synthetic tetrapeptide bioregulator (Lys-Glu-Asp-Ala) developed through Vladimir Khavinson’s research program at the St. Petersburg Institute of Bioregulation and Gerontology. It is associated with liver and immune tissue regulation and has been studied for effects on immune cell function, chromatin structure in hepatic cells, and age-related immune decline. FenaLife supplies Livagen in lyophilized form for research use only.
Research Background
Livagen belongs to the Khavinson bioregulator family. Its proposed liver and immune tissue associations have driven research into lymphocyte function, immune cell gene expression, and hepatic regulatory pathways. Studies from the Khavinson group have examined Livagen’s effects on T-cell activity, cytokine profiles, and chromatin decondensation in immune and hepatic cells.
Studied Mechanisms
Livagen is proposed to interact directly with nucleosomal DNA to promote chromatin decondensation, increasing accessibility for transcription factors in target tissues. Research has documented increased expression of immune-relevant genes in lymphocyte models following Livagen treatment, consistent with the chromatin accessibility hypothesis.
Molecular Profile
Molecular formula: C18H32N6O10. Molecular weight: 508.48 g/mol. Stable tetrapeptide. Purity: ≥98% by HPLC.
Storage and Handling
Store lyophilized Livagen at -20°C. Reconstitute with bacteriostatic water. Store reconstituted solution at 4°C and use within 4 to 6 weeks.
Research Use Only
For laboratory research purposes only. Not for human or veterinary use. Certificate of Analysis available per batch.